Congressional Republican support for bipartisan reforms to the US patent system for prescription drugs has been undercut by President Biden’s support for a waiver of intellectual property protections on COVID vaccines as part of the global response to the pandemic, according to House Oversight and Reform Committee ranking member James Comer, KY.
His comments suggest a broader fallout from Biden’s announcement earlier this month that it would pursue an IP waiver for COVID-19 vaccines, a prospect that was met with dismay from biopharma